↑ Rising
Business
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
Biotech
13 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.
◼ Archived
Business
🔮 fades ✓
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
◼ Archived
Business
🔮 fades ✗
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.
◼ Archived
Business
🔮 fades ✗
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
◼ Archived
Business
🔮 fades ✓
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
The First AI‑Designed Vaccine Has Been Tested in People. Here’s What Happened.
Clinical trials for the world's first AI-designed vaccine have entered human testing, marking a potential shift in medical development methodology.
◼ Archived
Health
🔮 fades ✗
Brain tumors: New vaccine offers patients hope for more time
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.
◼ Archived
Business
🔮 fades ✓
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
French biotech company Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion to expand its blood cancer pipeline.
◼ Archived
Business
🔮 fades ✓
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.